Anixa CAR-T Shows First Stable Disease at 3 Months in Ovarian Cancer
ANIX sits 29% above its 52-week low of $2.32.
Summary
Anixa reported the first case of stable disease at three months in its ovarian cancer CAR-T trial, with the first patient in the current cohort showing no progression. Multiple patients have survived over a year, one beyond two years, and no dose-limiting toxicities have been observed. This is a meaningful early efficacy signal for a small-cap biotech with a $102M market cap. The update follows insider buying by directors and the CFO in late September, suggesting confidence in the program. Next data readouts will be key to confirm durability.
At the time of this announcement, ANIX was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.6M. The 52-week trading range was $2.32 to $5.46. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.